Business Wire

CHINA-YIWU-FAIR

29.5.2019 13:04:06 CEST | Business Wire | Press release

Share
2019 China Yiwu Imported Commodities Fair Concludes, with Number of Professional Buyers up 48.41% Year-on-Year

2019 China Yiwu Imported Commodities Fair, a key platform to accelerate Yiwu’s opening up to the world, closed on May 26, 2019 in Yiwu City of China.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190529005470/en/

With an exhibition area of 50,000m2 , the Fair of this year gathered exhibitors from 85 countries and regions, including Spain, Italy, Germany, Russia, South Korea, Japan, Malaysia, India, Pakistan, Australia, and Tanzania, to show more than 100,000 varieties of daily necessities covering handcrafts, household goods, maternal and baby care, clothing accessories, food and beverage.

The four-day event attracted 119,600 person-times of visitors, including 48,800 professional buyers, up 48.41% compared to last year, from 81 oversea countries and all over China.

This year, three professional business matching meetings, namely Comprehensive Imported Commodities Purchasing Meeting, Spanish Products Purchasing Meeting and Chained Retail Enterprises Purchasing Meeting were held with great success. 50N Natural Ecology Group from Canada signed a million-dollar deal of flaxseed oil with a buyer from China’s Hunan Province. The renowned Dutch supermarket brand Albert Heijn (AH), with its unique operation mode and local supplies, attracted more than 100 potential franchisees including China’s leading chain supermarkets Yonghui and Trust-Mart.

As the guest of honor, Spain had a record number of over 40 companies exhibiting at the Fair. In addition, a series of activities such as the National Image Conference, Food and Wine Tasting, “España Fantasitica” Art Performance, and Charity Fair were held, presenting a unique Spanish style. Furthermore, special areas such as China International Import Expo (CIIE) Enterprises Area and Sister Cities Exchange Area were set up to boost the quality of the Fair.

In recent years, Yiwu has been accelerating its transformation to a city capable of buying and selling globally by seizing new opportunities in the upgrade of domestic consumption and deepening its reform in import trade. In the first quarter of this year, Yiwu's import trade increased by 150%, with the daily necessities imports increasing by 811%. Yiwu Imported Commodities Fair will continue to adhere to the “Belt and Road” initiative, and build itself as a benchmark for China's imported daily necessities.

Contact:

Chim Chen service@yiwufair.com

Link:

ClickThru

Social Media:

https://www.facebook.com/officialyiwufair/

https://www.facebook.com/yiwuimportfair/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye